Monica Mir

Dr. Monica Mir

Nanobioengineering Laboratory, Institute for Bioengineering of Catalonia (IBEC), Baldiri Reixach, 10, 08028 Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2007 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
TMTeresa Mairal
Teresa Mairal
Veli Cengiz OzalpVeli Cengiz Ozalp
Veli Cengiz Ozalp
PSPablo Lozano Sánchez
Pablo Lozano Sánchez
MMMonica Mir
Monica Mir
IKIoanis Katakis
Ioanis Katakis
CSCiara O Kathleen Sullivan
Ciara O Kathleen Sullivan

Verified
Journal Article
Open access
PDF file
JMJose Marrugo-Ramírez
Jose Marrugo-Ramírez
MMMonica Mir
Monica Mir
Josep Samitier MartíJosep Samitier Martí
Josep Samitier Martí
Cancer is one of the greatest threats facing our society, being the second leading cause of death globally. Currents strategies for cancer diagnosis consist of the extraction of a solid tissue from the affected area. This sample enables the study of specific biomarkers and the genetic nature of the tumor. However, the tissue extraction is risky and painful for the patient and in some cases is unavailable in inaccessible tumors. Moreover, a solid biopsy is expensive and time consuming and cannot be applied repeatedly. New alternatives that overcome these drawbacks are rising up nowadays, such as liquid biopsy. A liquid biopsy is the analysis of biomarkers in a non-solid biological tissue, mainly blood, which has remarkable advantages over the traditional method; it has no risk, it is non-invasive and painless, it does not require surgery and reduces cost and diagnosis time. The most studied cancer non-invasive biomarkers are circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. These circulating biomarkers play a key role in the understanding of metastasis and tumorigenesis, which could provide a better insight into the evolution of the tumor dynamics during treatment and disease progression. Improvements in isolation technologies, based on a higher grade of purification of CTCs, exosomes, and ctDNA, will provide a better characterization of biomarkers and give rise to a wide range of clinical applications, such as early detection of diseases, and the prediction of treatment responses due to the discovery of personalized tumor-related biomarkers.

1 March 2006 in Electrochemistry Communications
Verified
Journal Article
Closed access
MMMonica Mir
Monica Mir
MVMark Vreeke
Mark Vreeke
IKIoanis Katakis
Ioanis Katakis

29 March 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
SPSujey Palma-Florez
Sujey Palma-Florez
ALAdrián López-Canosa
Adrián López-Canosa
FMFrancisco Moralez-Zavala
Francisco Moralez-Zavala
OCOscar Castaño
Oscar Castaño
MKMarcelo J. Kogan
Marcelo J. Kogan
MMMonica Mir
Monica Mir
Background: The lack of predictive models that mimic the blood–brain barrier (BBB) hinders the development of effective drugs for neurodegenerative diseases. Animal models behave differently from humans, are expensive and have ethical constraints. Organ-on-a-chip (OoC) platforms offer several advantages to resembling physiological and pathological conditions in a versatile, reproducible, and animal-free manner. In addition, OoC give us the possibility to incorporate sensors to determine cell culture features such as trans-endothelial electrical resistance (TEER). Here, we developed a BBB-on-a-chip (BBB-oC) platform with a TEER measurement system in close distance to the barrier used for the first time for the evaluation of the permeability performance of targeted gold nanorods for theranostics of Alzheimer’s disease. GNR-PEG-Ang2/D1 is a therapeutic nanosystem previously developed by us consisting of gold nanorods (GNR) functionalized with polyethylene glycol (PEG), angiopep-2 peptide (Ang2) to overcome the BBB and the D1 peptide as beta amyloid fibrillation inhibitor, finally obtaining GNR-PEG-Ang2/D1 which showed to be useful for disaggregation of the amyloid in in vitro and in vivo models. In this work, we evaluated its cytotoxicity, permeability, and some indications of its impact on the brain endothelium by employing an animal-free device based on neurovascular human cells.Results: In this work, we fabricated a BBB-oC with human astrocytes, pericytes and endothelial cells and a TEER measuring system (TEER-BBB-oC) integrated at a micrometric distance of the endothelial barrier. The characterization displayed a neurovascular network and the expression of tight junctions in the endothelium. We produced GNR-PEG-Ang2/D1 and determined its non-cytotoxic range (0.05–0.4 nM) for plated cells included in the BBB-oC and confirmed its harmless effect at the highest concentration (0.4 nM) in the microfluidic device. The permeability assays revealed that GNR-PEG-Ang2/D1 cross the BBB and this entry is facilitated by Ang2 peptide. Parallel to the permeability analysis of GNR-PEG-Ang2/D1, an interesting behavior of the TJs expression was observed after its administration probably related to the ligands on the nanoparticle surface.Conclusions: BBB-oC with a novel TEER integrated setup which allow a correct read-out and cell imaging monitoring was proven as a functional and throughput platform to evaluate the brain permeability performance of nanotherapeutics in a physiological environment with human cells, putting forward a viable alternative to animal experimentation.

2 October 2009 in Electrophoresis
Verified
Journal Article
Closed access
PDF file
MMMonica Mir
Monica Mir
ACAntoni Homs Corbera
Antoni Homs Corbera
JSJosep Samitier
Josep Samitier

13 May 2022 in ACS Sensors
Verified
Journal Article
Open access
MMMonica Mir
Monica Mir
SPSujey Palma-Florez
Sujey Palma-Florez
Anna LagunasAnna Lagunas
Anna Lagunas
MLMaria José López-Martínez
Maria José López-Martínez
JSJosep Samitier
Josep Samitier
Over the most recent decades, the development of new biological platforms to study disease progression and drug efficacy has been of great interest due to the high increase in the rate of neurodegenerative diseases (NDDs). Therefore, blood-brain barrier (BBB) as an organ-on-a-chip (OoC) platform to mimic brain-barrier performance could offer a deeper understanding of NDDs as well as a very valuable tool for drug permeability testing for new treatments. A very attractive improvement of BBB-oC technology is the integration of detection systems to provide continuous monitoring of biomarkers in real time and a fully automated analysis of drug permeably, rendering more efficient platforms for commercialization. In this Perspective, an overview of the main BBB-oC configurations is introduced and a critical vision of the BBB-oC platforms integrating electronic read out systems is detailed, indicating the strengths and weaknesses of current devices, proposing the great potential for biosensors integration in BBB-oC. In this direction, we name potential biomarkers to monitor the evolution of NDDs related to the BBB and/or drug cytotoxicity using biosensor technology in BBB-oC.